Does drug promotion adversely influence doctor's abilities to make the best decisions for patients?

Australasian Psychiatry

Volumn 9, Issue 2, 2001, Pages 95-99

  Jureidini, J ^a   Mansfield, P ^a  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

Advertising; Ethics; Pharmaceutical industry; Psychiatry; Research support

Indexed keywords

AMLODIPINE BESYLATE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDROCHLOROTHIAZIDE; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT;

AWARENESS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; FINANCIAL MANAGEMENT; HEALTH PROMOTION; HUMAN; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL LITERATURE; OBSESSION; PATIENT CARE; PRESCRIPTION; PSYCHIATRIST; PUBLIC RELATIONS; REVIEW;

EID: 0034939677     PISSN: 10398562     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1665.2001.00313.x     Document Type: Review

References (29)

1. Health outcomes associated with calcium antagonists compared with other first-line anti-hypertensive therapies: A meta-analysis of random controlled trials
2. Drug companies and CME: Prohibition, declaration and or engagement?
3. Memoirs of methods used to sell drugs
4. Management views on industry issues, pressures and consultants
5. Interactions between physicians and the pharmaceutical industry: What does the literature say?
6. The effects of pharmaceutical firm enticements on physician prescribing patterns: There's no such thing as a free lunch
7. Conflict of interest in the debate over calcium-channel antagonists
8. Pharmaceutical advertisements in leading medical journals: Experts' assessments
9. The pharmaceutical representative and medical practitioner encounter: Implications for quality use of medicines
10. A cautionary tale
11. Separating the wheat from the chaff: Identifying fallacies in pharmaceutical promotion
12. Drug advertisements that go straight to the hippocampus
13. MaLAM, a medical lobby for appropriate marketing of pharmaceuticals